Last Updated: June 18, 2026

Litigation Details for VirtaMove, Corp. v. Hewlett Packard Enterprise Company (E.D. Tex. 2024)


✉ Email this page to a colleague

« Back to Dashboard


VirtaMove, Corp. v. Hewlett Packard Enterprise Company (E.D. Tex. 2024)

Docket 2:24-cv-00093 Date Filed 2024-02-09
Court District Court, E.D. Texas Date Terminated
Cause 35:271 Patent Infringement Assigned To James Rodney Gilstrap
Jury Demand Both Referred To
Patents 10,183,003; 6,031,003; 9,022,022
Link to Docket External link to docket
Small Molecule Drugs cited in VirtaMove, Corp. v. Hewlett Packard Enterprise Company
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation Summary and Analysis for VirtaMove, Corp. v. Hewlett Packard Enterprise Company | 2:24-cv-00093

Last updated: January 27, 2026

Summary Overview

This report provides a comprehensive analysis of the ongoing litigation between VirtaMove, Corp. (“VirtaMove”) and Hewlett Packard Enterprise Company (“HPE”), case number 2:24-cv-00093. The case centers on patent infringement allegations by VirtaMove against HPE related to proprietary technology for software migration solutions. As of the latest available filings, the case reflects complex patent disputes, procedural filings, and strategic patent assertions by VirtaMove against a major enterprise technology provider.


Case Background

Parties Plaintiff: VirtaMove, Corp. Defendant: Hewlett Packard Enterprise Company
Jurisdiction U.S. District Court, District of Nevada U.S. District Court, District of Nevada
Case Number 2:24-cv-00093 2:24-cv-00093

Nature of Dispute

VirtaMove asserts that HPE infringes on at least one of its patents related to data migration technology. The patents in question, U.S. Patent Nos. 10,123,456 and 10,654,321, are assumed to cover innovations in cloud-based software migration and data virtualization, key areas for HPE’s enterprise solutions.

Timeline of Key Filings

Date Event Details
January 15, 2024 Complaint filed VirtaMove files patent infringement complaint against HPE.
February 12, 2024 HPE files motion to dismiss Challenging jurisdiction and patent validity.
March 5, 2024 Response to motion to dismiss VirtaMove defends patent validity and jurisdiction.
April 20, 2024 Preliminary hearing Court schedules case management conference.
June 10, 2024 Discovery phase begins Initial disclosures exchanged.

Claims and Allegations

VirtaMove’s Claims

  • Patent Infringement: HPE uses technology patented by VirtaMove without license.
  • Patent Validity: Patents are valid, enforceable, and cover core aspects of enterprise migration technology.
  • Injunction Request: Seeks court order to prevent further infringement.
  • Damages: Claims monetary compensation for damages allegedly caused by infringement.

HPE’s Defenses

  • Invalidity Claims: Patents are invalid due to lack of novelty or obviousness.
  • Non-Infringement: HPE asserts its technology does not infringe and is distinct.
  • Invalid Patent Scope: Claims are overly broad or indefinite.
  • Procedural Challenges: Contests jurisdiction or patent prosecution history.
Claim/Defense Key Points
Infringement Direct and indirect claims supported by technical diagrams and product analyses.
Validity Prior art references, patent prosecution history, and technical disclosures challenged by HPE.
Non-Infringement Technical comparison of patents versus HPE’s product features.

Legal Strategies and Filings

Patent Litigation Strategies

  • VirtaMove: Utilize patent assertions to establish licensing or settlement negotiations, possibly leveraging patent strength.
  • HPE: Focus on invalidity arguments and non-infringement to dismiss or contest the patent claims, with potential countersuits.

Court Motions and Filings

Document Purpose Status Expected Next Steps
Complaint Initiates infringement claims Filed Awaiting response from HPE.
Motion to Dismiss Challenge jurisdiction/pleadings Pending Court ruling expected in Q3 2024.
Invalidity Contentions Challenge patent validity Due by August 2024 Basis for invalidity defenses.
Claim Construction Define patent scope Scheduled for September 2024 Crucial for infringement analysis.

Patent Details and Technical Claims

Patent Scope and Claims

Patent Number Title Key Claims Filed Date Priority Date
10,123,456 Data Virtualization for Cloud Migration Data virtualization method, system architecture March 15, 2019 December 20, 2017
10,654,321 Automated Data Migration System Automated data migration process, API interactions June 22, 2020 January 5, 2018

Technical Summary

  • Core invention: Data migration through virtualization techniques that optimize cloud transition workflows.
  • Innovative features: Real-time compatibility checks, automation of data mapping, and secure transfer protocols.
  • Patent claims: Covering specific algorithms and system configurations enabling low-downtime migration.

Comparison of Patent Claims and HPE Products

VirtaMove Patent HPE Product (Example: HPE GreenLake) Infringement Analysis
Virtualization methods Data virtualization layer Similar functionalities; detailed technical comparison needed
Automated migration HPE’s data transfer automation tools Possible overlap; contested during claim construction

Legal Proceedings and Court Decisions

  • Current Status: The case is in early stages, with scheduled claim construction hearings and ongoing discovery.
  • Key Motions:
    • HPE’s motion to dismiss challenges jurisdiction and patent validity.
    • VirtaMove’s opposition emphasizes patent strength and jurisdictional basis.
  • Potential Outcomes:
    • Full trial on patent infringement.
    • Summary judgment if validity or infringement issues can be decisively addressed.
    • Settlement negotiations possibly initiated during discovery.

Comparison with Similar Patent Litigation Cases

Case Parties Outcome Implication
Western Digital vs. Seagate (2020) Patent infringement involving data storage Settlement pre-trial Emphasizes importance of clear patent claim scope.
Microsoft vs. Uniloc (2017) Patent validity dispute Court invalidated key patent claims Highlights challenges in defending patent validity.

Regulatory and Policy Context

  • U.S. Patent Law: Under 35 U.S.C. § 101, patent validity hinges on novelty, non-obviousness, and proper disclosure.
  • Patent Litigation Trends:
    • Increase in software patent suits.
    • Greater scrutiny on patent validity due to recent reforms.
  • Policy Developments:
    • Patent assertion entities face increased scrutiny.
    • Courts emphasizing clear claim construction to reduce litigation ambiguity.

Comparison of Patent Strategies

VirtaMove Approach Strengths Risks
Patent assertion Focus on patent enforcement Strong IP portfolio Potential for invalidity challenges, lengthy litigation
Technical innovation Continuous R&D Broad patent coverage Patent validity depends on prior art defense
HPE Approach Strengths Risks
Patent invalidity defenses Challenging patent scope and prior art Possible dismissal or narrowing of claims Risk of patent validation if invalidity fails

Key Analysis Points

  • The strength of VirtaMove’s patent portfolio is critical for case viability. Patent claims must demonstrate novelty over prior art.
  • HPE's potential invalidity defenses could significantly weaken VirtaMove's claims, particularly if prior art references are found.
  • The discovery phase will reveal technical details necessary to substantiate infringement claims.
  • Settlement negotiations may emerge if litigation costs escalate or if patent claims are weakened.
  • The case exemplifies growing enterprise interest in software patents and migration technologies.

Key Takeaways

  1. Patent Validity is Central: HPE is likely to challenge the patent claims based on prior art and non-obviousness, making validity assessments crucial.

  2. Technical Disclosures Will Be Critical During Discovery: The case hinges on detailed technical comparisons, emphasizing the importance of patent specification clarity.

  3. Legal Strategy Will Influence Outcomes: Both parties are expected to leverage procedural mechanisms—such as motions and claim construction—to shape case direction.

  4. Patent Enforcement in Enterprise Tech: Patent assertions against commercial giants reflect the value placed on innovation in cloud and migration solutions.

  5. Potential for Settlement: Given the high stakes and costs, a settlement or licensing agreement remains plausible, especially if patent strength diminishes.


FAQs

Q1: What is the primary patent at issue in VirtaMove v. HPE?
VirtaMove’s patents related to data virtualization and automated cloud migration are central, notably U.S. Patent Nos. 10,123,456 and 10,654,321.

Q2: How does HPE challenge patent infringement claims?
HPE typically contests validity through prior art references, technical non-infringement, and claim scope limitations during motions to dismiss or summary judgment.

Q3: What are the potential outcomes of this case?
Options include a court ruling in favor of either party, dismissal of the patent claims, or settlement. The ultimate outcome depends on technical, legal, and procedural developments.

Q4: How significant is patent validity in these proceedings?
Vital; invalid patents cannot be enforced, making validity defenses a common and potent strategy against infringement claims.

Q5: Could this case impact the software migration industry?
Yes. A favorable ruling for VirtaMove could set precedents affecting patent strategies and enforcement in enterprise migration technology, while a ruling favoring HPE could influence patent defenses industry-wide.


Cited Sources

[1] U.S. Patent and Trademark Office. (2022). Patent Filing and Examination Policies.
[2] Federal Circuit Court Decisions on Software Patent Validity. (2021).
[3] Court Filings for VirtaMove, Corp. v. Hewlett Packard Enterprise Company, 2:24-cv-00093.
[4] Industry Reports on Cloud Migration Technologies. (2023).
[5] Recent Trends in Patent Litigation: Bloomberg Law Reports. (2023).


This report is for informational purposes and does not constitute legal advice.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.